

## Author Index

- Andersen, D.O., Weber, N.D., Wood, S.G., Hughes, B.G., Murray, B.K. and North, J.A., In vitro virucidal activity of selected anthraquinones and anthraquinone derivatives, 185
- Andrei, G., see Snoeck, R., 1
- Andries, K., Dewindt, B., Snoeks, J., Willebrords, R., Stokbroekx, R. and Lewi, P.J., A comparative test of fifteen compounds against all known human rhinovirus serotypes as a basis for a more rational screening program (Mini-Review), 213
- Andries, K., see White, E.L., 255
- Ankel, H., see Bader, Th., 341
- Araullo-Cruz, T., see Gordon, Y.J., 11
- Awan, A.R., see Field, H.J., 29
- Bader, Th., Yamada, Y. and Ankel, H., Antiviral activity of the prostanoid clavulone II against vesicular stomatitis virus, 341
- Balestra, E., see Del Gobbo, V., 65
- Balzarini, J., see Naesens, L., 53
- Balzarini, J., see Neyts, J., 41
- Balzarini, J., see Palu, G., 115
- Bilello, J.A., see Eiseman, J.L., 307
- Birch, G.M., see Nassiri, M.R., 135
- Bobek, M., see Kaufman, H.E., 225
- Bohm, R., see Soike, K.F., 17
- Buckheit, Jr., R.W., see White, E.L., 255
- Caliò, R., see Del Gobbo, V., 65
- Carpendale, M.T.F. and Freeberg, J.K., Ozone inactivates HIV at noncytotoxic concentrations, 279
- Ceruzzi, M., see Kmetz, M.E., 173
- Cheng, Y.C., see Kaufman, H.E., 225
- Chirigos, M.A., see White, E.L., 255
- Clausen, H., see Hansen, J.-E.S., 231
- Cohen, J.S., Antisense oligodeoxynucleotides as antiviral agents (Mini-Review), 121
- Coleman, L.A., see Nassiri, M.R., 135
- Colin, J.-N., see Sinet, M., 163
- Craig, J.C., Duncan, I.B., Hockley, D., Grief, C., Roberts, N.A. and Mills, J.S., Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase, 295
- De Castro, L.M., Kern, E.R., De Clercq, E., Ghaffar, A., Mayer, E.P., Vogt, P.E. and Gangemi, J.D., Phosphonylethoxymethyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS, 101
- De Clercq, E., see De Castro, L.M., 101
- De Clercq, E., see Gordon, Y.J., 11
- De Clercq, E., see Maudgal, P.C., 93
- De Clercq, E., see Naesens, L., 53
- De Clercq, E., see Neyts, J., 41
- De Clercq, E., see Palu, G., 115
- De Clercq, E., see Snoeck, R., 1
- Del Gobbo, V., Foli, A., Balestra, E., Villani, N., Marini, S., Perno, C.F. and Caliò, R., Immunomodulatory activity of phosphonylethoxymethyl adenine (PMEA), a potent anti-HIV nucleoside analogue, on in vivo murine models, 65
- Desforges, B., see Sinet, M., 163
- Dewindt, B., see Andries, K., 213
- Drach, J.C., see Nassiri, M.R., 135
- Duncan, I.B., see Craig, J.C., 295
- Dutschman, G.E., see Kaufman, H.E., 225
- Ebner, J.P., see Hoover, E.A., 77
- Eiseman, J.L., Yetter, R.A., Fredrickson, T.N., Shapiro, S.G., MacAuley, C. and Bilello, J.A., Effect of 3'azidothymidine administered in drinking water or by continuous infusion on the development of MAIDS, 307
- Erzurum, S., see Gordon, Y.J., 11
- Field, H.J., Awan, A.R. and de la Fuente, R., Isolation of equine herpesvirus-1 mutants in the presence of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine: demonstration of resistance in vitro and in vivo, 29
- Foli, A., see Del Gobbo, V., 65
- Fredrickson, T.N., see Eiseman, J.L., 307
- Freeberg, J.K., see Carpendale, M.T.F., 279
- de la Fuente, R., see Field, H.J., 29
- Fukuma, M., Seto, Y. and Yamase, T., In vitro antiviral activity of polyoxotungstate (PM-19) and other polyoxometalates against herpes simplex virus, 327
- Gangemi, J.D., see De Castro, L.M., 101
- Germany, J.M., see White, E.L., 255
- Ghaffar, A., see De Castro, L.M., 101
- Gordon, Y.J., Romanowski, E., Araullo-Cruz, T., Seaberg, L., Erzurum, S., Tolmam, R. and De Clercq, E., Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2'-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro, 11
- Grief, C., see Craig, J.C., 295

- Hansen, J.-E.S., Nielsen, C., Clausen, H., Mathiesen, L.R. and Nielsen, J.O., Effect of anti-carbohydrate antibodies on HIV infection in a monocytic cell line (U937), 231
- Hitchcock, M.J.M., see Soike, K.F., 17
- Hockley, D., see Craig, J.C., 295
- Holliday, J. and Williams, M.V., Inhibition of herpes simplex virus types 1 and 2 replication in vitro by mercurithio analogs of deoxyuridine, 197
- Hoover, E.A., Ebner, J.P., Zeidner, N.S. and Mullins, J.I., Early therapy of feline leukemia virus infection (FeLV-FAIDS) with 9-(2-phosphonylmethoxyethyl)adenine (PMEA), 77
- Huang, J.-L., see Soike, K.F., 17
- Hudson, J.L., see Nassiri, M.R., 135
- Hughes, B.G., see Andersen, D.O., 185
- Janssen, P.A.J., see White, E.L., 255
- Kaufman, H.E., Varnell, E.D., Cheng, Y.C., Bobek, M., Thompson, H.W. and Dutschman, G.E., Suppression of ocular herpes recurrences by a thymidine kinase inhibitor in squirrel monkeys, 225
- Kern, E.R., see De Castro, L.M., 101
- Kmetz, M.E., Ceruzzi, M. and Schwartz, J., Vmw65 phosphorothioate oligonucleotides inhibit HSV KOS replication and Vmw65 protein synthesis, 173
- Kunita, N., see Otake, T., 241
- Kurimura, T., see Otake, T., 241
- Launay, O., see Sinet, M., 163
- Lewi, P.J., see Andries, K., 213
- MacAuley, C., see Eiseman, J.L., 307
- Marini, S., see Del Gobbo, V., 65
- Martin, J.C., see Soike, K.F., 17
- Mathiesen, L.R., see Hansen, J.-E.S., 231
- Maudgal, P.C. and De Clercq, E., Effects of phosphonylmethoxyalkyl-purine and -pyrimidine derivatives on TK+ and TK- HSV-1 keratitis in rabbits, 93
- Mayer, E.P., see De Castro, L.M., 101
- Mills, J.S., see Craig, J.C., 295
- Miyano, K., see Otake, T., 241
- Mori, H., see Otake, T., 241
- Morimoto, M., see Otake, T., 241
- Mullins, J.I., see Hoover, E.A., 77
- Murray, B.K., see Andersen, D.O., 185
- Naesens, L., Balzarini, J. and De Clercq, E., Single-dose administration of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the prophylaxis of retrovirus infection in vivo, 53
- Nakashima, H., see Otake, T., 241
- Nassiri, M.R., Turk, S.R., Birch, G.M., Coleman, L.A., Hudson, J.L., Pudlo, J.S., Townsend, L.B. and Drach, J.C., Activity of acyclic halogenated tubercidin analogs against human cytomegalovirus and in uninfected cells, 135
- Neyts, J., Snoeck, R., Balzarini, J. and De Clercq, E., Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro, 41
- Neyts, J., see Snoeck, R., 1
- Nicholas, J.A., see Rubino, K.L., 265
- Nielsen, C., see Hansen, J.-E.S., 231
- Nielsen, J.O., see Hansen, J.-E.S., 231
- Nokta, M.A., see Shafik, H.M., 205
- North, J.A., see Andersen, D.O., 185
- Otake, T., Miyano, K., Mori, H., Morimoto, M., Ueba, N., Kunita, N., Nakashima, H. and Kurimura, T., Anti-HIV-1 activity of sulfated amphotericin B in vitro, 241
- Palu, G., Stefanelli, S., Rassu, M., Parolin, C., Balzarini, J. and De Clercq, E., Cellular uptake of phosphonylmethoxyalkylpurine derivatives (Short Communication), 115
- Pancheva, S.N., Potentiating effect of ribavirin on the anti-herpes activity of acyclovir, 151
- Parolin, C., see Palu, G., 115
- Pauwels, R., see White, E.L., 255
- Perno, C.F., see Del Gobbo, V., 65
- Pocidalò, J.-J., see Sinet, M., 163
- Pollard, R.B., see Shafik, H.M., 205
- Pudlo, J.S., see Nassiri, M.R., 135
- Rassu, M., see Palu, G., 115
- Roberts, N.A., see Craig, J.C., 295
- Romanowski, E., see Gordon, Y.J., 11
- Ross, L.J., see White, E.L., 255
- Rubino, K.L., Tarpley, W.G. and Nicholas, J.A., Effects of a soluble CD4 and CD4-Pseudomonas exotoxin A chimeric protein on human peripheral blood lymphocytes: lymphocyte activation and anti-HIV activity in vitro, 265
- Schols, D., see Snoeck, R., 1
- Schwartz, J., see Kmetz, M.E., 173
- Seaberg, L., see Gordon, Y.J., 11
- Seto, Y., see Fukuma, M., 327
- Shafik, H.M., Nokta, M.A. and Pollard, R.B., Recombinant human interferon beta ser protects against zidovudine-induced genetic damage in AIDS patients, 205
- Shannon, W.M., see White, E.L., 255

- Shapiro, S.G., see Eiseman, J.L., 307
- Sinet, M., Desforbes, B., Launay, O., Colin, J.-N. and Pocidalo, J.-J., Factors influencing zidovudine efficacy when administered at early stages of Friend virus infection in mice, 163
- Snoeck, R., Schols, D., Andrei, G., Neyts, J. and De Clercq, E., Antiviral activity of anti-cytomegalovirus agents (HPMPC, HPMPA) assessed by a flow cytometric method and DNA hybridization technique, 1
- Snoeck, R., see Neyts, J., 41
- Snoeks, J., see Andries, K., 213
- Soike, K.F., Huang, J.-L., Zhang, J.-Y., Bohm, R., Hitchcock, M.J.M. and Martin, J.C., Evaluation of infrequent dosing regimens with (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (S-HPMPC) on simian varicella infection in monkeys, 17
- Stefanelli, S., see Palu, G., 115
- Stokbroekx, R., see Andries, K., 213
- Tarpley, W.G., see Rubino, K.L., 265
- Thompson, H.W., see Kaufman, H.E., 225
- Tolmam, R., see Gordon, Y.J., 11
- Townsend, L.B., see Nassiri, M.R., 135
- Turk, S.R., see Nassiri, M.R., 135
- Ueba, N., see Otake, T., 241
- Varnell, E.D., see Kaufman, H.E., 225
- Villani, N., see Del Gobbo, V., 65
- Vogt, P.E., see De Castro, L.M., 101
- Weber, N.D., see Andersen, D.O., 185
- White, E.L., Buckheit, Jr., R.W., Ross, L.J., Germany, J.M., Andries, K., Pauwels, R., Janssen, P.A.J., Shannon, W.M. and Chirigos, M.A., A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates, 255
- Willebrords, R., see Andries, K., 213
- Williams, M.V., see Holliday, J., 197
- Wood, S.G., see Andersen, D.O., 185
- Yamada, Y., see Bader, Th., 341
- Yamase, T., see Fukuma, M., 327
- Yetter, R.A., see Eiseman, J.L., 307
- Zeidner, N.S., see Hoover, E.A., 77
- Zhang, J.-Y., see Soike, K.F., 17





## Subject Index

- AIDS**, Human immunodeficiency virus type 1 (HIV-1), Sulfated amphotericin B, Amphotericin B methyl ester, 243
- AIDS**, Soluble CD4, sCD4-183, sCD4-PE40, HIV, *Pseudomonas* exotoxin A, 267
- AIDS**, ZDV, Interferon beta, Chromosomal damage, 205
- AZT**, Animal model of HIV infection, Friend virus, Chemoprophylaxis, 163
- Acyclovir**, Ribavirin, Combination chemotherapy, HSV-1, PRV, Keratitis, 151
- Adenovirus**, (S)-HPMPC, (S)-HPMPA, 2'-nor-cyclic GMP, 11
- Amphotericin B methyl ester**, Human immunodeficiency virus type 1 (HIV-1), Sulfated amphotericin B, AIDS, 243
- Animal model of HIV infection**, AZT, Friend virus, Chemoprophylaxis, 163
- Anthraquinone**, Hypericin, Emodin, Virucidal, Tween-80, 185
- Antibody-dependent enhancement**, HIV, U937, Neutralization, Carbohydrate, 231
- Antiherpetic agent**, Polyoxometalate, PM-19, Keggin-type structure, 327
- Antisense**, Drug development, Oligonucleotide, Translation arrest, Transcription arrest, 121
- Antiviral therapy**, Azidothymidine, Zidovudine, MAIDS, LP-BM5, MuLV, 307
- Azidothymidine**, Zidovudine, MAIDS, Antiviral therapy, LP-BM5, MuLV, 307
- BVDU**, HSV-1 keratitis, TK — HSV-1, HPMPA, HPMPC, PMEA, Phosphonylethoxymethyl derivative, 93
- Carbohydrate**, HIV, U937, Neutralization, Antibody-dependent enhancement, 231
- Cellular uptake**, HPMPA, PMEA, Endocytosis, Nucleoside transport, 115
- Chemoprophylaxis**, AZT, Animal model of HIV infection, Friend virus, 163
- Chemotherapy**, Equine herpesvirus-1, EHV-1, Resistance, Phosphonyl, Nucleoside analog, 29
- Chromosomal damage**, ZDV, Interferon beta, AIDS, 205
- Clavulone**, Vesicular stomatitis virus, Prostaglandin, 341
- Combination chemotherapy**, Acyclovir, Ribavirin, HSV-1, PRV, Keratitis, 151
- Cytomegalovirus**, HPMPC, DNA integrity, 41
- Cytomegalovirus**, Herpes, 7-Deaza adenosine, Pyrolopyrimidine, Nucleoside, 135
- 7-Deaza adenosine**, Cytomegalovirus, Herpes, Pyrolopyrimidine, Nucleoside, 135
- DNA hybridization**, Human cytomegalovirus, Flow cytometry, 1
- DNA integrity**, Cytomegalovirus, HPMPC, 41
- Dendritic keratitis**, Herpes simplex virus, Recurrent ocular herpetic disease, Thymidine kinase, Virus inhibitor, 225
- Drug development**, Antisense, Oligonucleotide, Translation arrest, Transcription arrest, 121
- dUTPase**, Herpes simplex virus, Mercurithio-deoxyuridine analog, 197
- Emodin**, Anthraquinone, Hypericin, Virucidal, Tween-80, 185
- Endocytosis**, HPMPA, PMEA, Cellular uptake, Nucleoside transport, 115
- Equine herpesvirus-1**, EHV-1, Resistance, Phosphonyl, Nucleoside analog, Chemotherapy, 29
- FeLV-FAIDS**, Feline leukemia virus, 9-(2-Phosphonylmethoxyethyl)adenine (PMEA), Immunodeficiency, Retrovirus, 78
- Feline leukemia virus**, 9-(2-Phosphonylmethoxyethyl)adenine (PMEA), Immunodeficiency, Retrovirus, FeLV-FAIDS, 78
- Flow cytometry**, Human cytomegalovirus, DNA hybridization, 1
- Friend virus**, AZT, Animal model of HIV infection, Chemoprophylaxis, 163
- HIV**, Human immunodeficiency virus, Moloney murine sarcoma virus, MSV, Single dose administration, 53
- HIV**, Ozone, Noncytotoxic, Virus inhibitor, 279
- HIV**, Proteinase, Inhibitor, 295
- HIV**, Soluble CD4, sCD4-183, sCD4-PE40, AIDS, *Pseudomonas* exotoxin A, 265
- HIV**, U937, Neutralization, Antibody-dependent enhancement, Carbohydrate, 231
- HIV-1**, TIBO, HIV-2, Reverse transcriptase, Novel RNA template, 255
- HIV-2**, TIBO, HIV-1, Reverse transcriptase, Novel RNA template, 255
- HPMPA**, HSV-1 keratitis, TK — HSV-1, BVDU, HPMPC, PMEA, Phosphonylmethoxyalkyl derivative, 93
- HPMPA**, PMEA, Cellular uptake, Endocytosis, Nucleoside transport, 115

- HPMPC therapy**, Murine acquired immunodeficiency syndrome, MAIDS, Opportunistic infection, PMEA therapy, 102
- HPMPC**, Cytomegalovirus, DNA integrity, 41
- HPMPC**, HSV-1 keratitis, TK — HSV-1, BVDU, HPMPA, PMEA, Phosphonylmethoxyalkyl derivative, 93
- HPMPC**, Simian varicella virus, Monkey, 17
- HSV-1 keratitis**, TK — HSV-1, BVDU, HPMPA, HPMPC, PMEA, Phosphonylmethoxyalkyl derivative, 93
- HSV-1**, Acyclovir, Ribavirin, Combination chemotherapy, PRV, Keratitis, 151
- Herpes simplex virus**, dUTPase, Mercurithio-deoxyuridine analog, 197
- Herpes simplex virus**, Dendritic keratitis, Recurrent ocular herpetic disease, Thymidine kinase, Virus inhibitor, 225
- Herpes**, Cytomegalovirus, 7-Deaza adenosine, Pyrrolopyrimidine, Nucleoside, 135
- Human cytomegalovirus**, DNA hybridization, Flow cytometry, 1
- Human immunodeficiency virus**, HIV, Moloney murine sarcoma virus, MSV, Single dose administration, 53
- Human immunodeficiency virus type 1 (HIV-1)**, Sulfated amphotericin B, Amphotericin B methyl ester, AIDS, 243
- Hypericin**, Anthraquinone, Emodin, Virucidal, Tween-80, 185
- Immunodeficiency**, Feline leukemia virus, 9-(2-Phosphonylmethoxyethyl)adenine (PMEA), Retrovirus, FeLV-FAIDS, 78
- Inhibitor**, HIV, Proteinase, 295
- Interferon**, Nucleoside analog, 9-(2-phosphonylmethoxyethyl)adenine, NK cytotoxicity, Interleukin-1, Interleukin-2, 65
- Interferon beta**, ZDV, Chromosomal damage, AIDS, 205
- Interleukin-1**, Nucleoside analog, 9-(2-phosphonylmethoxyethyl)adenine, NK cytotoxicity, Interferon, Interleukin-2, 65
- Interleukin-2**, Nucleoside analog, 9-(2-phosphonylmethoxyethyl)adenine, NK cytotoxicity, Interferon, Interleukin-1, 65
- Keratitis**, Acyclovir, Ribavirin, Combination chemotherapy, HSV-1, PRV, 151
- Keggin-type structure**, Polyoxometalate, PM-19, Antiherpetic agent, 327
- LP-BM5**, Azidothymidine, Zidovudine, MAIDS, Antiviral therapy, MuLV, 307
- MAIDS**, Azidothymidine, Zidovudine, Antiviral therapy, LP-BM5, MuLV, 307
- MAIDS**, Murine acquired immunodeficiency syndrome, Opportunistic infection, HPMPC therapy, PMEA therapy, 102
- MSV**, Human immunodeficiency virus, HIV, Moloney murine sarcoma virus, Single dose administration, 53
- Mercurithio-deoxyuridine analog**, Herpes simplex virus, dUTPase, 197
- Moloney murine sarcoma virus**, Human immunodeficiency virus, HIV, MSV, Single dose administration, 53
- Monkey**, Simian varicella virus, HPMPC, 17
- MuLV**, Azidothymidine, Zidovudine, MAIDS, Antiviral therapy, LP-BM5, 307
- Murine acquired immunodeficiency syndrome**, MAIDS, Opportunistic infection, HPMPC therapy, PMEA therapy, 102
- NK cytotoxicity**, Nucleoside analog, 9-(2-phosphonylmethoxyethyl)adenine, Interferon, Interleukin-1, Interleukin-2, 65
- Neutralization**, HIV, U937, Antibody-dependent enhancement, Carbohydrate, 231
- Noncytotoxic**, HIV, Ozone, Virus inhibitor, 279
- Novel RNA template**, TIBO, HIV-1, HIV-2, Reverse transcriptase, 255
- Nucleoside analog**, Equine herpesvirus-1, EHV-1, Resistance, Phosphonyl, Chemotherapy, 29
- Nucleoside analog**, 9-(2-phosphonylmethoxyethyl)adenine, NK cytotoxicity, Interferon, Interleukin-1, Interleukin-2, 65
- Nucleoside transport**, HPMPA, PMEA, Cellular uptake, Endocytosis, 115
- Nucleoside**, Cytomegalovirus, Herpes, 7-Deaza adenosine, Pyrrolopyrimidine, 135
- Oligodeoxynucleotide**, Phosphorothioate modification, Protein synthesis inhibition, Replication inhibition, 173
- Oligonucleotide**, Antisense, Drug development, Translation arrest, Transcription arrest, 121
- Opportunistic infection**, Murine acquired immunodeficiency syndrome, MAIDS, HPMPC therapy, PMEA therapy, 102
- Ozone**, HIV, Noncytotoxic, Virus inhibitor, 279
- 9-(2-Phosphonylmethoxyethyl)adenine (PMEA)**, Feline leukemia virus, Immunodeficiency, Retrovirus, FeLV-FAIDS, 78
- 9-(2-phosphonylmethoxyethyl)adenine**, Nucleoside analog, NK cytotoxicity, Interferon, Interleukin-1, Interleukin-2, 65
- PM-19**, Polyoxometalate, Keggin-type structure, Antiherpetic agent, 327

- PMEA therapy**, Murine acquired immunodeficiency syndrome, MAIDS, Opportunistic infection, HPMPc therapy, 102
- PMEA**, HPMPa, Cellular uptake, Endocytosis, Nucleoside transport, 115
- PMEA**, HSV-1 keratitis, TK — HSV-1, BVDU, HPMPa, HPMPc, Phosphonylethoxyalkyl derivative, 93
- PRV**, Acyclovir, Ribavirin, Combination chemotherapy, HSV-1, Keratitis, 151
- Phosphonyl**, Equine herpesvirus-1, EHV-1, Resistance, Nucleoside analog, Chemotherapy, 29
- Phosphonylethoxyalkyl derivative**, HSV-1 keratitis, TK — HSV-1, BVDU, HPMPa, HPMPc, PMEA, 93
- Phosphorothioate modification**, Oligodeoxynucleotide, Protein synthesis inhibition, Replication inhibition, 173
- Polyoxometalate**, PM-19, Keggin-type structure, Antihypertensive agent, 327
- Prostaglandin**, Vesicular stomatitis virus, Clavulone, 341
- Protein synthesis inhibition**, Phosphorothioate modification, Oligodeoxynucleotide, Replication inhibition, 173
- Proteinase**, HIV, Inhibitor, 295
- Pseudomonas* exotoxin A, Soluble CD4, sCD4-183, sCD4-PE40, AIDS, HIV, 265
- Pyrrolopyrimidine**, Cytomegalovirus, Herpes, 7-Deaza adenosine, Nucleoside, 135
- Rational screening program**, Rhinovirus, Screening, antiviral, 213
- Recurrent ocular herpetic disease**, Dendritic keratitis, Herpes simplex virus, Thymidine kinase, Virus inhibitor, 225
- Replication inhibition**, Phosphorothioate modification, Oligodeoxynucleotide, Protein synthesis inhibition, 173
- Resistance**, Equine herpesvirus-1, EHV-1, Phosphonyl, Nucleoside analog, Chemotherapy, 29
- Retrovirus**, Feline leukemia virus, 9-(2-Phosphonylethoxyethyl)adenine (PMEA), Immunodeficiency, FeLV-FAIDS, 78
- Reverse transcriptase**, TIBO, HIV-1, HIV-2, Novel RNA template, 255
- Rhinovirus**, Rational screening program, Screening, antiviral, 213
- Ribavirin**, Acyclovir, Combination chemotherapy, HSV-1, PRV, Keratitis, 151
- Screening**, antiviral, Rational screening program, Rhinovirus, 213
- (S)-HPMPa**, 2'-nor-cyclic GMP, (S)-HPMPc, Adenovirus, 11
- (S)-HPMPc**, (S)-HPMPa, 2'-nor-cyclic GMP, Adenovirus, 11
- sCD4-183**, Soluble CD4, sCD4-PE40, AIDS, HIV, *Pseudomonas* exotoxin A, 265
- sCD4-PE40**, Soluble CD4, sCD4-183, AIDS, HIV, *Pseudomonas* exotoxin A, 265
- Simian varicella virus**, HPMPc, Monkey, 17
- Single dose administration**, Human immunodeficiency virus, HIV, Moloney murine sarcoma virus, MSV, 53
- Soluble CD4**, sCD4-183, sCD4-PE40, AIDS, HIV, *Pseudomonas* exotoxin A, 265
- Sulfated amphotericin B**, Human immunodeficiency virus type 1 (HIV-1), Amphotericin B methyl ester, AIDS, 243
- TIBO**, HIV-1, HIV-2, Reverse transcriptase, Novel RNA template, 255
- TK — HSV-1**, HSV-1 keratitis, BVDU, HPMPa, HPMPc, PMEA, Phosphonylethoxyalkyl derivative, 93
- Thymidine kinase**, Dendritic keratitis, Herpes simplex virus, Recurrent ocular herpetic disease, Virus inhibitor, 225
- Transcription arrest**, Antisense, Drug development, Oligonucleotide, Translation arrest, 121
- Translation arrest**, Antisense, Drug development, Oligonucleotide, Transcription arrest, 121
- Tween-80**, Anthraquinone, Hypericin, Emodin, Virucidal, 185
- U937**, HIV, Neutralization, Antibody-dependent enhancement, Carbohydrate, 231
- Vesicular stomatitis virus**, Prostaglandin, Clavulone, 341
- Virucidal**, Anthraquinone, Hypericin, Emodin, Tween-80, 185
- Virus inhibitor**, Dendritic keratitis, Herpes simplex virus, Recurrent ocular herpetic disease, Thymidine kinase, 225
- Virus inhibitor**, HIV, Ozone, Noncytotoxic, 279
- ZDV**, Interferon beta, Chromosomal damage, AIDS, 205
- Zidovudine**, Azidothymidine, MAIDS, Antiviral therapy, LP-BM5, MuLV, 307